Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Aditxt (NASDAQ: ADTX) Is in Focus After New Convertible Note Financing

Aditxt (NASDAQ: ADTX) announced a senior secured note purchase agreement involving its wholly owned subsidiary Ignite Proteomics LLC.

Nitish Kishor | 10 June 2026

Why PMGC Holdings (NASDAQ: ELAB) Is in Focus Amid Space Infrastructure Opportunities

PMGC Holdings (NASDAQ: ELAB) recently emphasized its ITAR-registered and AS9100-certified manufacturing capabilities as interest in space infrastructure and satellite-related projects continues to grow.

Nitish Kishor | 10 June 2026

Why AXT, Inc. (NASDAQ: AXTI) Stock Is Up 12% Today

Why AXT, Inc. (NASDAQ: AXTI) Stock Is Surging Today

Nitish Kishor | 10 June 2026

Why Amkor Technology (NASDAQ: AMKR) Stock Is Up 3% Today

Why Amkor Technology (NASDAQ: AMKR) Stock Is Rising Today

Nitish Kishor | 10 June 2026

Why KLA Corporation (NASDAQ: KLAC) Stock Is Up 7% Today

Why KLA Corporation (NASDAQ: KLAC) Stock Is Surging Today

Nitish Kishor | 10 June 2026

Why Aehr Test Systems (NASDAQ: AEHR) Is in Focus as Semiconductor Stocks Rebound

Why Aehr Test Systems (NASDAQ: AEHR) Is Drawing Investor Attention

Nitish Kishor | 10 June 2026

Why Opendoor Technologies (NASDAQ: OPEN) Stock Is Up 6% Today

Why Opendoor Technologies (NASDAQ: OPEN) Stock Is Rising

Nitish Kishor | 10 June 2026

Why Basel Medical Group (NASDAQ: BMGL) Is in Focus Following Reverse Stock Split Approval

Basel Medical Group (NASDAQ: BMGL) announced that it will implement a 1-for-12 reverse stock split effective June 22, 2026.

Nitish Kishor | 10 June 2026

Why CervoMed (NASDAQ: CRVO) Is in Focus Following Private Placement Financing

CervoMed (NASDAQ: CRVO) announced a private placement expected to generate approximately $10.5 million in upfront gross proceeds.

Nitish Kishor | 10 June 2026

Why Rafael Holdings (NYSE: RFL) Is in Focus Following Key Phase 3 Trial Milestone

Rafael Holdings (NYSE: RFL) announced the successful completion of the Last Patient Last Visit milestone for the final 96-week treatment period in its global Phase 3 TransportNPC clinical trial.

Nitish Kishor | 10 June 2026
Support

Hi! How can we help you today?

Loading…